Delivery of melarsoprol using folate-targeted PEGylated cyclodextrin-based nanoparticles for hepatocellular carcinoma

Simple item page
dc.check.date2024-03-20
dc.check.infoAccess to this article is restricted until 12 months after publication by request of the publisher.
dc.contributor.authorLi, Ya-Nanen
dc.contributor.authorShi, Xiaojuen
dc.contributor.authorSun, Dandanen
dc.contributor.authorHan, Shulanen
dc.contributor.authorZou, Yifangen
dc.contributor.authorWang, Lingzhien
dc.contributor.authorYang, Leileien
dc.contributor.authorLi, Yutongen
dc.contributor.authorShi, Yingen
dc.contributor.authorGuo, Jianfengen
dc.contributor.authorO'Driscoll, Caitriona M.en
dc.contributor.funderNational Natural Science Foundation of China
dc.contributor.funderDepartment of Science and Technology of Jilin Province
dc.contributor.funderFirst Hospital of Jilin University, China
dc.contributor.funderJilin University, China
dc.contributor.funderScience Foundation Ireland
dc.contributor.funderEuropean Regional Development Fund
dc.date.accessioned2023-04-26T15:18:16Z
dc.date.available2023-04-26T15:57:45Zen
dc.date.available2023-04-26T15:18:16Z
dc.date.issued2023-03-20
dc.date.updated2023-04-26T14:57:46Z
dc.description.abstractHepatocellular carcinoma (HCC) is the most common type of primary liver cancer, and has become one of the most lethal malignancies in the world. Although chemotherapy remains a cornerstone of cancer therapy, the number of chemotherapeutic drugs approved for HCC is low, and emerging therapeutics are needed. Melarsoprol (MEL) is an arsenic-containing drug, and has been applied in the treatment of human African trypanosomiasis at the late stage. In this study, the potential of MEL for HCC therapy was investigated for the first time using in vitro and in vivo experimental approaches. A folate-targeted polyethylene glycol-modified amphiphilic cyclodextrin nanoparticle was developed for safe, efficient and specific delivery of MEL. Consequently, the targeted nanoformulation achieved cell-specific uptake, cytotoxicity, apoptosis and migration inhibition in HCC cells. Furthermore, the targeted nanoformulation significantly prolonged the survival of mice with orthotopic tumor, without causing toxic signs. This study indicates the potential of the targeted nanoformulation as an emerging chemotherapy option for treating HCC.en
dc.description.sponsorshipNational Natural Science Foundation of China (81770026); Science and Technology Department of Jilin Province (YDZJ202201ZYTS528); First Hospital of Jilin University, China (JDYYJCHX2020001); Jilin University, China (2022B40; 2022JBGS05)
dc.description.statusPeer revieweden
dc.description.versionAccepted Version
dc.format.mimetypeapplication/pdfen
dc.identifier.articleid122791
dc.identifier.citationLi, Y.-N., Shi, X., Sun, D., Han, S., Zou, Y., Wang, L., Yang, L., Li, Y., Shi, Y., Guo, J. and O'Driscoll, C. M. (2023) 'Delivery of melarsoprol using folate-targeted PEGylated cyclodextrin-based nanoparticles for hepatocellular carcinoma', International Journal of Pharmaceutics, 636, 122791 (8pp). doi: 10.1016/j.ijpharm.2023.122791
dc.identifier.doi10.1016/j.ijpharm.2023.122791en
dc.identifier.endpage8
dc.identifier.issn0378-5173
dc.identifier.journaltitleInternational Journal of Pharmaceutics
dc.identifier.startpage1
dc.identifier.urihttps://hdl.handle.net/10468/14407
dc.identifier.volume636
dc.language.isoenen
dc.publisherElsevier B.V.
dc.relation.projectinfo:eu-repo/grantAgreement/SFI/SFI Research Centres/13/RC/2073/IE/CÚRAM - Centre for Research in Medical Devices/
dc.relation.projectinfo:eu-repo/grantAgreement/SFI/SFI Research Centres/12/RC/2275/IE/Synthesis and Solid State Pharmaceutical Centre (SSPC)/
dc.relation.projectinfo:eu-repo/grantAgreement/SFI/SFI Research Centres/12/RC/2275/IE/Synthesis and Solid State Pharmaceutical Centre (SSPC)/
dc.rights© 2023, Elsevier B.V. All rights reserved. This manuscript version is made available under the CC BY-NC-ND 4.0 license.
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectLiver cancer
dc.subjectDrug delivery
dc.subjectNanoparticle
dc.subjectArsenicals
dc.subjectChemotherapy
dc.titleDelivery of melarsoprol using folate-targeted PEGylated cyclodextrin-based nanoparticles for hepatocellular carcinoma
dc.typeArticle (peer-reviewed)
Files
Original bundle
Now showing 1 - 3 of 3
Thumbnail Image
Name:
IJP Manuscript.pdf
Size:
1.69 MB
Format:
Adobe Portable Document Format
Description:
Accepted Version
Download
Thumbnail Image
Name:
1-s2.0-S0378517323002119-mmc1.docx
Size:
50.59 KB
Format:
Microsoft Word XML
Description:
Supplementary Data
Download
Thumbnail Image
Name:
IJP Manuscript.docx
Size:
9.48 MB
Format:
Microsoft Word XML
Description:
Author's original accepted version
Collections
Pharmacy - Journal Articles